文献速递神经MR

压缩感知与敏感度编码3D CEST成像对胶质瘤的分级价值

Grading of gliomas using 3D CEST imaging with compressed sensing and sensitivity encoding.
PubMed 文献 · Eur J Radiol · 2022-12-15

本研究纳入28例胶质瘤患者(低级别12例、高级别16例),在3T MR上比较2D CEST与3D CEST(CS-SENSE)测得的肿瘤MTRasym at 3.5 ppm。三种测量方法均与Ki-67LI呈中度正相关,且高级别胶质瘤MTRasym显著高于低级别,诊断效能相当;3D CEST可逐层提供MTRasym信息。

要点

  • 3D CEST(CS-SENSE)可逐层测量MTRasym at 3.5 ppm,诊断效能与2D CEST相当。
  • 高级别胶质瘤的MTRasym at 3.5 ppm显著高于低级别胶质瘤。
  • MTRasym at 3.5 ppm与Ki-67LI呈中度正相关,提示可无创反映增殖活性。

核心结论

  • 3D CEST成像可逐层提供肿瘤MTRasym at 3.5 ppm,对低级别与高级别胶质瘤的鉴别诊断效能与2D CEST相当。

研究设计与样本

  • 单中心研究纳入28例胶质瘤患者(低级别12例、高级别16例),平均年龄51.0±13.9岁,男13例、女15例。
  • 所有患者使用3T MR扫描仪采集,3D CEST成像采集9层,2D CEST成像采集1层。
  • 由两名放射科技师分别在FLAIR图像高信号区周围勾画ROI,比较2D、3Dall和3Dmax三种方法的MTRasym at 3.5 ppm。
  • 以Ki-67标记指数(Ki-67LI)为参考,评估MTRasym at 3.5 ppm与Ki-67LI的相关性,并用ROC分析评价诊断效能。

关键影像表现/征象

  • 三种方法测得的MTRasym at 3.5 ppm与Ki-67LI均呈中度正相关。
  • 三种方法均显示高级别胶质瘤的MTRasym at 3.5 ppm显著大于低级别胶质瘤。
  • 各病例的信号强度随层面位置而变化。

诊断标准与关键数值

  • 三种方法(2D、3Dall、3Dmax)的诊断效能相当,但原文未报告具体敏感度、特异度、AUC及阈值。

临床应用与阅片要点

  • 3D CEST可逐层评估肿瘤MTRasym at 3.5 ppm,有助于反映肿瘤异质性,但需注意信号强度随层面位置变化。
  • MTRasym at 3.5 ppm与Ki-67LI中度相关,可作为无创评估胶质瘤增殖潜能的补充指标。

局限性

  • 样本量较小(共28例),为单中心研究。
  • 原文未报告敏感度、特异度、AUC及阈值等具体诊断效能数值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: We evaluated the usefulness of three-dimensional (3D) chemical exchange saturation transfer (CEST) imaging with compressed sensing and sensitivity encoding (CS-SENSE) for differentiating low-grade gliomas (LGGs) from high-grade gliomas (HGGs).

METHODS: We evaluated 28 patients (mean age 51.0 ± 13.9 years, 13 males, 15 females) including 12 with LGGs and 16 with HGGs, all acquired using a 3 T magnetic resonance (MR) scanner. Nine slices were acquired for 3D CEST imaging, and one slice was acquired for two-dimensional (2D) CEST imaging. Two radiological technologists each drew a region of interest (ROI) surrounding the high-signal-intensity area(s) on the fluid-attenuated inversion recovery image of each patient. We compared the magnetization transfer ratio asymmetry (MTRasym) at 3.5 ppm in the tumors among the (i) single-slice 2D CEST imaging ("2D"), (ii) all tumor slices of the 3D CEST imaging (3Dall), and (iii) a representative tumor slice of 3D CEST imaging (maximum signal intensity [3Dmax]). The relationship between the MTRasym at 3.5 ppm values measured by these three methods and the Ki-67 labeling index (LI) of the tumors was assessed. Diagnostic performance was evaluated with a receiver operating characteristic analysis. The Ki-67LI and MTRasym at 3.5 ppm values were compared between the LGGs and HGGs.

RESULTS: A moderate positive correlation between the MTRasym at 3.5 ppm and the Ki-67LI was observed with all three methods. All methods proved a significantly larger MTRasym at 3.5 ppm for the HGGs compared to the LGGs. All methods showed equivalent diagnostic performance. The signal intensity varied depending on the slice position in each case.

CONCLUSIONS: The 3D CEST imaging provided the MTRasym at 3.5 ppm for each slice cross-section; its diagnostic performance was also equivalent to that of 2D CEST imaging.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Wada, Togao, Tokunaga, et al. Grading of gliomas using 3D CEST imaging with compressed sensing and sensitivity encoding. Eur J Radiol. 2022. PMID: 36528957. doi:10.1016/j.ejrad.2022.110654

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。